X-ray crystallographic and fluorometric analysis of the interactions of rhein to human serum albumin

Chemical Biology and Drug Design

Volumn 83, Issue 2, 2014, Pages 167-173

  Li, Mei ^a,b   Lee, Philbert ^c   Zhang, Yao ^b   Ma, Zhiyuan ^b   Yang, Feng ^b   Zhou, Zuping ^b   Wu, Xiaoyang ^c   Liang, Hong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGXI NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

fluorescence spectroscopy; human serum albumin; protein drug interaction; rhein; X ray crystallography

Indexed keywords

HUMAN SERUM ALBUMIN; HYDROXYL GROUP; OXYGEN; RHEIN;

ARTICLE; ATOM; BINDING AFFINITY; FLUORESCENCE SPECTROSCOPY; FLUOROMETRY; HYDROGEN BOND; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

FLUORESCENCE SPECTROSCOPY; HUMAN SERUM ALBUMIN; PROTEIN-DRUG INTERACTION; RHEIN; X-RAY CRYSTALLOGRAPHY;

ANTHRAQUINONES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FLUOROMETRY; HUMANS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN; WATER;

EID: 84892501734     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12208     Document Type: Article

References (40)

1. Peters T., (1995) All About Albumin: Biochemistry, Genetics And Medical Applications. San Diego: Academic Press.
2. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P., (2012) Human serum albumin: from bench to bedside. Mol Aspects Med; 33: 209-290.
3. Yamasaki K., Chuang V.T., Maruyama T., Otagiri M., (2013) Albumin-drug interaction and its clinical implication. Biochim Biophys Acta (Epub ahead of print).
4. Kragh-Hansen U., (2013) Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochim Biophys Acta (Epub ahead of print).
5. Stewart A.J., Blindauer C.A., Berezenko S., Sleep D., Sadler P.J., (2003) Interdomain zinc site on human albumin. Proc Natl Acad Sci USA; 100: 3701-3706.
6. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S., (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol; 353: 38-52.
7. Sadler P.J., Viles J.H., (1996) 1H and (113) Cd NMR investigations of Cd(2+) and Zn(2+) binding sites on serum albumin: competition with Ca(2+), Ni(2+), Cu(2+), and Zn(2+). Inorg Chem; 35: 4490-44968.
8. Zunszain P.A., Ghuman J., McDonagh A.F., Curry S., (2008) Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol; 381: 394-406.
9. He X.M., Carter D.C., (1992) Atomic structure and chemistry of human serum albumin. Nature; 358: 209-215.
10. Yamaguchi S., Aldini G., Ito S., Morishita N., Shibata T., Vistoli G., Carini M., Uchida K., (2010) Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146. J Am Chem Soc; 132: 824-832.
11. Curry S., (2009) Lessons from the crystallographic analysis of small molecule binding to Human serum albumin. Drug Metab Pharmacokinet; 24: 342-357.
12. Simard J.R., Zunszain P.A., Ha C.E., Yang J.S., Bhagavan N.V., Petitpas I., Curry S., Hamilton J.A., (2005) Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci USA; 102: 17958-17963.
13. Guo S., Shi X., Yang F., Chen L., Meehan E.J., Bian C., Huang M., (2009) Structural basis of transport of lysophospholipids by human serum albumin. Biochem J; 423: 23-30.
14. Yang F., Bian C., Zhu L., Zhao G., Huang Z., Huang M., (2007) Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol; 157: 348-355.
15. Curry S., Mandelkow H., Brick P., Franks N., (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol; 5: 827-835.
16. He Z.H., Zhou R., He M.F., Lau C.B., Yue G.G., Ge W., But P.P., (2011) Anti-angiogenic effect and mechanism of rhein from Rhizoma Rhei. Phytomedicine; 18: 470-478.
17. Chen Y.Y., Chiang S.Y., Lin J.G., Ma Y.S., Liao C.L., Weng S.W., Lai T.Y., Chung J.G., (2010) Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol; 36: 1113-1120.
18. Gao Q., Qin W.S., Jia Z.H., Zheng J.M., Zeng C.H., Li L.S., Liu Z.H., (2010) Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med; 76: 27-33.
19. Chen B., Ye F., Yu L., Jia G., Huang X., Zhang X., Peng S., et al. (2012) Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc; 134: 17963-17971.
20. Brahmachari B., Chatterjee S., Ghosh A., (2009) Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol; 28: 1193-1198.
21. Legendre F., Heuze A., Boukerrouche K., Leclercq S., Boumediene K., Galera P., Domagala F., Pujol J.P., Ficheux H., (2009) Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis. Scand J Rheumatol; 38: 104-111.
22. Martin G., Bogdanowicz P., Domagala F., Ficheux H., Pujol J.P., (2003) Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation; 27: 233-246.
23. Domagala F., Martin G., Bogdanowicz P., Ficheux H., Pujol J.P., (2006) Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for diacerein effects in osteoarthritis. Biorheology; 43: 577-587.
24. Deffaud J., Kirchmeyer M., Domagala F., Ficheux H., Netter P., Bianchi A., Jouzeau J.Y., (2008) Modulatory effect of rhein on IL-1alpha-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs. Biorheology; 45: 439-455.
25. Colmenarejo G., (2003) In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev; 3: 275-301.
26. Gokara M., Sudhamalla B., Amooru D.G., Subramanyam R., (2010) Molecular interaction studies of trimethoxy flavone with human serum albumin. PLoS ONE; 1: 8834-8842.
27. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., et al,. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature; 435: 677-681.
28. Hein K.L., Kragh-Hansen U., Morth J.P., Jeppesen M.D., Otzen D., Møller J.V., Nissen P., (2011) Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J Struct Biol; 171: 353-360.
29. DeLano W.L., (2004) The PyMol Molecular Graphics System. San Carlos, CA: DeLano ScientiWc.
30. Kamtekar N., Pandey A., Agrawal N., Pissurlenkar R.R., Borana M., Ahmad B., (2013) Interaction of multimicrobial synthetic inhibitor 1,2-bis(2-benzimidazolyl)-1,2-ethanediol with serum albumin: spectroscopic and computational studies. PLoS ONE; 8: e53499.
31. Hany I., Sothea K., Jean-Pierre N., Françoise N., (2010) Interactions between Antimalarial Indolone-N-oxide Derivatives and Human Serum Albumin. Biomacromolecules; 11: 3341-3351.
32. Chatterjee T., Pal A., Dey S., Chatterjee B.K., (2012) Chakrabarti P. Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling. PLoS ONE; 7: e38372.
33. Abou-Zied O.K., AlShihi O.I., (2008) Characterization of subdomain IIA binding site of human serum albumin in its native, unfolded, and refolded states using small molecular probes. J Am Chem Soc; 130: 10793-10801.
34. Kang J., Liu Y., Xie M.X., Li S., Jiang M., Wang Y.D., (2004) Interactions of human serum albumin with chlorogenic acid and ferulic acid. Biochim Biophys Acta; 1674: 205-214.
35. Bhattacharya A.A., Grune T., Curry S., (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol; 303: 721-732.
36. Yang F., Yue J., Ma L., Ma Z., Li M., Wu X., Liang H., (2012) Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin. Mol Pharm; 9: 3259-3265.
37. Zhu L., Yang F., Chen L., Meehan E.J., Huang M., (2008) A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J Struct Biol; 162: 40-49.
38. Kratz F., (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release; 132: 171-183.
39. Neumann E., Frei E., Funk D., Becker M.D., Schrenk H.H., Müller-Ladner U., Fiehn C., (2010) Native albumin for targeted drug delivery. Expert Opin Drug Deliv; 7: 915-925.
40. Elsadek B., Kratz F., (2012) Impact of albumin on drug delivery-new applications on the horizon. J Control Release; 157: 4-28.